
The candidate vaccine’s next steps will be going through the FDA’s Biologics License Application process.
Fougera and Protherics announce increased DigiFab production to counteract shortage.
Fougera and Protherics, Inc. have announced an increase in production of their digoxin immune fab (ovine) (






